Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice |
| |
Authors: | Joana?MAC?Gil Marcel?Leist Natalija?Popovic Patrik?Brundin Email author" target="_blank">?sa?PetersénEmail author |
| |
Institution: | (1) Section for Neuronal Survival, Wallenberg Neuroscience Center, BMC A10, Lund University, Sweden;(2) Disease Biology, H. Lundbeck A/S, Copenhagen, Denmark |
| |
Abstract: | Background Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. Both excitotoxicity and oxidative stress have been proposed to play important roles in the pathogenesis of HD. Since
no effective treatment is available, this study was designed to explore the therapeutic potential of erythropoietin (EPO),
a cytokine that has been found to prevent excitotoxicity, and to promote neurogenesis. To avoid the side effects of a raised
hematocrit, we used asialoerythropoietin (asialoEPO), a neuroprotective variant of EPO that lacks erythropoietic effects in
mice. R6/2 transgenic HD mice were treated with this cytokine from five to twelve weeks of age. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|